Mike Colley started having problems with his memory and decision making a few years ago.
He is one of only a few dozen UK patients included in the global study who has received a monthly infusion of donanemab for the past two years.
The 80-year-old from Kent said he feels “incredibly lucky” to be on the immunotherapy drug.
While visiting a London clinic for treatment, he told the BBC: “I seem to be getting more confident every day and I’m sure this will work out and they’re going to get all this crap off my head.”
Mike Colley started having problems with his memory and decision making a few years ago. Pictured with his son Mark
The treatment won’t cure his Alzheimer’s, but his family suggested his condition stopped getting worse.
His son, Mark, said it was very hard to watch him struggle at first.
He said, “It was really hard watching him struggle with processing information and solving problems. But I think the decline is now reaching a plateau.”
He added, “I never thought I would see my father so full of life again. Now we have hope and two years ago we didn’t. That’s just an incredible difference.’
Historic research results today showed that donanemab can slow early-stage Alzheimer’s disease by up to 60 percent.
Experts hailed the breakthrough as the “turning point” in the fight against the vicious disease and described it as a “defining moment” for dementia research.
It is the second treatment after lecanemab to offer hope to patients in what experts have hailed as ‘the decade of Alzheimer’s’, where it could one day be compared to other long-term conditions such as asthma or diabetes.
Scientists said it also ended the decades-long debate over whether the buildup of sticky plaques, or amyloid, is at least partially responsible for the degenerative disease.
The drug halted mental decline for more than a year in about half of the patients, according to findings presented this afternoon at the Alzheimer’s Association International Conference in Amsterdam.
Mr. Colley surprised his family at his own 80th birthday party by singing Frank Sinatra’s My Way. He told BBC News: ‘That’s the confidence I have now. I would never have done that twelve months ago.’
Donanemab is given once a month to Alzheimer’s patients by intravenous infusion. The monoclonal antibody — a man-made version of proteins produced by the body to fight harmful substances — travels to the brain. Once in the organ, donanemab binds to toxic accumulations of amyloid plaque – a hallmark sign of the memory-robbing disease. This prompts immune cells known as microglia to clear them
Created by Eli Lilly and Company, the US pharmaceutical company announced that it had already applied for FDA approval and is expected to apply in the UK within 6 months.
It means that patients can be treated with it within 18 months.
The drug – given as a monthly infusion – was found to be most effective in people under the age of 75 in the earliest stages of the disease.
Researchers studied nearly 1,800 people with early-stage Alzheimer’s, with patients receiving either donanemab or a placebo for 18 months.
Those in the earliest stage of the disease with mild cognitive impairment had the greatest benefit, with a 60 percent delay in decline compared to placebo.
In early Alzheimer’s patients whose brain scans showed low or average levels of a protein called tau, the drug was found to slow clinical decline by 35 percent.
When the results were combined for people with different levels of this protein, there was a 22.3 percent slowdown in disease progression, according to findings published in the Journal of the American Medical Association.
Dr. Richard Oakley, deputy director of research and innovation at Alzheimer’s Society, said: ‘This really is a turning point in the fight against Alzheimer’s and the science is proving that it is possible to slow the disease down.
‘Treatments like donanemab are the first steps towards a future where Alzheimer’s disease can be viewed as a long-term condition alongside diabetes or asthma – people may have to live with it, but they can receive treatments that allow them to effectively manage their symptoms and carry on to live a fulfilled life.” The drug works by using the immune system to clear amyloid — toxic plaque buildup in the brain that stops brain cells from communicating.
In addition to slowing the worsening of symptoms by an average of 4.5 to 7.5 months, the drug also meant patients could continue their daily activities for longer, researchers said.
Researchers revealed today that donanemab slows cognitive decline in Alzheimer’s disease by 35 percent by clearing toxic plaques in the brain
Experts said patients should be aware of the risks of the treatment so they can choose whether to take these drugs or not. Stock: Scan of a patient’s brain
However, there were some serious side effects, such as brain swelling and bleeding in some patients, as well as three deaths from taking the medication.
Experts said patients should be aware of the risks of the treatment so they can choose whether to take these drugs or not.
Dr. Susan Kohlhaas, from Alzheimer’s Research UK, said today’s announcement “marks another milestone” after decades of research.
She said: ‘We are entering a new era where Alzheimer’s disease may become treatable.
‘As a first-generation potential treatment, the effects of donanemab are modest. But these results further confirm that removing amyloid from the brain can change the course of Alzheimer’s disease and help people affected by this devastating disease if treated at the right time.
‘On the other hand, it is clear that donanemab is associated with side effects, which can be very serious for some. Regulators will have to weigh these benefits and risks before licensing it for use.”